Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

J Acevedo

Showing results (61-70 of 64) with videos related to

Pageof 7
Sort By:
You have reached the last page of results.This site can display upto 64 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2025
TRADE: a phase II trial to assess the tolerability of abemaciclib dose escalation in early-stage HR-positive/HER2-negative breast cancerE L Mayer, D Trapani, S-E Kim, et al.
ESMO Open|July 6, 2026
TRADE: tolerability of adjuvant abemaciclib at 6 months after initial dose escalation in patients with early-stage HR-positive/HER2-negative breast cancerI Schlam, D Trapani, S-E Kim, et al.
Nutrients|June 11, 2020
A Glycosaminoglycan-Rich Fraction from Sea Cucumber <i>Isostichopus badionotus</i> Has Potent Anti-Inflammatory Properties In Vitro and In VivoLeticia Olivera-Castillo, George Grant, Nuvia Kantún-Moreno, et al.
Journal of Clinical Lipidology|January 10, 2021
Familial hypercholesterolemia in Mexico: Initial insights from the national registryRoopa Mehta, Alexandro J Martagon, Gabriela A Galan Ramirez, et al.
Pageof 7

Showing results (61-70 of 64) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 64 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 19, 2025
TRADE: a phase II trial to assess the tolerability of abemaciclib dose escalation in early-stage HR-positive/HER2-negative breast cancerE L Mayer, D Trapani, S-E Kim, et al.
ESMO Open|July 6, 2026
TRADE: tolerability of adjuvant abemaciclib at 6 months after initial dose escalation in patients with early-stage HR-positive/HER2-negative breast cancerI Schlam, D Trapani, S-E Kim, et al.
Nutrients|June 11, 2020
A Glycosaminoglycan-Rich Fraction from Sea Cucumber <i>Isostichopus badionotus</i> Has Potent Anti-Inflammatory Properties In Vitro and In VivoLeticia Olivera-Castillo, George Grant, Nuvia Kantún-Moreno, et al.
Journal of Clinical Lipidology|January 10, 2021
Familial hypercholesterolemia in Mexico: Initial insights from the national registryRoopa Mehta, Alexandro J Martagon, Gabriela A Galan Ramirez, et al.
Pageof 7